Aminopyridine Compounds Inhibit Gingipain Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for the proteases called gingipains produced by Porphyromonas gingivalis, which are associated with various diseases including periodontal disease, Alzheimer's, and other disorders, necessitating the development of potent nonpeptidic compounds to inhibit these enzymes.
Innovation Solution
The development of specific compounds according to Formulas I and III, or their pharmaceutically acceptable salts, which are designed to inhibit gingipain activity, including the use of pharmaceutical compositions containing these compounds to treat diseases associated with P. gingivalis infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used, then existing therapy options are available, but effective inhibition of gingipain activity is not achieved
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (Formula I and Formula III) that optimize binding affinity to gingipain active sites. By varying structural parameters such as substituent groups, ring sizes, and stereochemistry, the invention achieves potent inhibition of gingipain activity where previous treatments failed
Solution Approach 2:
The patent introduces nonpeptidic compounds as intermediary substances that mediate between the host and gingipain enzymes. These compounds act as competitive inhibitors, binding to the enzyme active site and preventing substrate interaction, thereby blocking the harmful proteolytic activity of gingipains without requiring peptide structures
2Reliability
If peptidic inhibitors are used, then gingipain inhibition can be achieved, but issues with selectivity and off-target effects occur
Solution Approach 1:
The patent applies local quality by designing compounds where specific functional groups and structural features are localized to interact with particular residues in the gingipain active site. The nonpeptidic nature allows precise positioning of inhibitory moieties while avoiding the promiscuity of peptidic substrates, enhancing selectivity for gingipains over other proteases
Solution Approach 2:
Instead of using peptidic structures that mimic natural substrates (which can lead to off-target effects), the patent inverts the approach by using nonpeptidic structures that maintain inhibitory function while eliminating substrate-like properties. This inversion provides better selectivity by avoiding recognition by other protease systems
Data Source
AI summary
The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.